Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26360925 | 1.00 | ADORA1 (0.61) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL22402607 | 0.93 | ADORA3 (0.61) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL22393065 | 0.93 | ADORA3 (0.61) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL21118872 | 0.90 | SLC29A1 (0.60) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL6896076 | 0.89 | ADORA1 (0.66) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL6896080 | 0.89 | ADORA1 (0.66) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL28680450 | 0.84 | ADORA1 (0.72) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL29408565 | 0.84 | ADORA1 (0.72) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL26370816 | 0.84 | ADORA1 (0.72) | ADORA1ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL1060588 | 0.84 | ADORA1 (0.72) | ADORA1ADORA3SLC29A1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-18 | — | — | US | disclosed |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | WUXI PHARMATECH HEALTHCARE FUND I L.P. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | SHANGHAI XINQI WU FILM AND TELEVISION INVESTMENT CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| CN-113348181-A | DC-SIGN antibody conjugates comprising a STING agonist | 诺华股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10975114-B2 | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof | CHINOOK THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | LUMINEX INTERNATIONAL (CN) | 2020-09-10 | — | — | US | disclosed |
| CN-111565726-A | Compositions and methods for modulating immune responses by activating alpha protein kinase 1 | 上海药苑生物科技有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20200199169-A1 | BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| CN-110831954-A | Bis 2 '-5' -RR- (3 'F-A) (3' F-A) cyclic dinucleotide compounds and application thereof | 艾杜罗生物科技公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110799218-A | Antibody conjugates comprising STING agonists | 诺华股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017560-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADORA1 56/4885ADORA3 197/4885SLC29A1 2172/4885 |
| US-11186606-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-20200283468-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-11149051-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-11840551-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | ADORA1 805/4885ADORA3 492/4885SLC29A1 1107/4885 |
| US-20200199169-A1 | BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | STING1, IRF3, IFNAR1 | ADORA1 140/4885ADORA3 69/4885SLC29A1 2554/4885 |
| US-20240124511-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-11773131-B2 | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
| US-10975114-B2 | Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof | STING1, IRF3, IFNAR1 | ADORA1 144/4885ADORA3 80/4885SLC29A1 2616/4885 |
| US-20210403501-A1 | COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 | PHKA1, PHKA2, PRKCA | ADORA1 344/4885ADORA3 739/4885SLC29A1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.